Abstract award: Good tolerance of post-RP radiotherapy ± STADT

Dr. Paul Sargos (Institute Bergonie, Bordeaux, France) presented the first results of the GETUG-AFU 22 study and won the second prize in the EAU20 Best Abstract Awards Oncology.

Dr. Paul Sargos (Institute Bergonie, Bordeaux, France) presented the first results of the GETUG-AFU 22 study and won the second prize in the EAU20 Best Abstract Awards for Oncology1.

The GETUG-AFU 22 study, a multicentre randomized phase-2 trial, compared 6 months of degarelix short-term androgen deprivation therapy (STADT) in combination with radiotherapy (RT) and with RT alone as salvage treatment for patients with detectable prostate-specific antigen (PSA) levels after radical prostatectomy (RP). The primary efficacy endpoint was event-free survival, which will be reported later this year. Key secondary endpoints were toxicity (as measured by CTCAE V4.0) and quality of life (QLQ-C30 and QLQ-PR25) results.

Dr. Sargos presented the key secondary endpoints in 125 patients with localized prostate cancer, treated by RP, with a PSA level post-RP ≥ 0.2 ng/mL and ≤ 2 ng/mL at randomization and N0 M0 on imaging were included. Median PSA level was 0.3 ng/mL (0.09-1.82) post-RP and 0.6 ng/mL (0.12-3.65) at randomisation.

With a median follow-up of 38 months, the 2-years toxicity showed no differences in late genitourinary or gastrointestinal toxicity between the 2 arms (P=0.145). No difference was seen between the 2 arms for erectile dysfunction, while 2 patients in each arm reported grade-3 cardiovascular events (in the RT-alone arm, tight coronary stenosis, and femoral arteritis; in the RT + STADT arm, pulmonary embolism, and cardiac arrhythmia). The number of second cancers was not significantly different between the arms.

Quality of life was evaluated in 59% of patients in the RT arm and 77% in the RT + STADT arm. At 12 months, QLQ-PR25 related symptoms were significantly higher in the RT + STADT arm (P=0.04), but these data normalized by 24 months when no significant difference in QLQC-30 or QLQ-PR25 outcomes was reported. This study highlights the good tolerance of postoperative radiotherapy.

1. Sargos P, et al. Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase ii trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy. 2020 European Association of Urology Virtual Congress. July 17-26, 2020 Abstract PT925.

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.